XEN® implantation: an effective strategy to stop glaucoma progression despite prior minimally invasive glaucoma surgery.

Anja-Maria DavidsMilena PahlitzschEckart BertelmannAnna-Karina MaierSibylle Winterhalter

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2022)

XEN® implantation effectively and significantly lowers the IOP and number of glaucoma therapy in POAG in the 36-month follow-up with a favorable profile of side effects and few complications. In case of IOP, general anesthesia has a significant positive influence on the survival rate, whereas prior SLT or MIGS does not have significant impact.

Keyphrases

minimally invasive
optic nerve
cataract surgery
coronary artery bypass
risk factors
stem cells
optical coherence tomography
atrial fibrillation
acute coronary syndrome
percutaneous coronary intervention
free survival